Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gocovri in Levodopa-Induced Dyskinesia (EASE LID 3)
NCT02274766Phase 3Completed
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing ADS-5102 with Placebo (2 arms). Primary endpoint: Unified Dyskinesia Rating Scale Total Score at 12 weeks. Started Oct 2014; status: completed.
02
Drugs
amantadine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT02274766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274766.